274 related articles for article (PubMed ID: 26160848)
41. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
42. FOXM1-Induced PRX3 Regulates Stemness and Survival of Colon Cancer Cells via Maintenance of Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Heo HJ; Kim HK; Bae KB; Park YH; Kim SU; Kim JM; Kim N; Ko KS; Rhee BD; Han J
Gastroenterology; 2015 Oct; 149(4):1006-16.e9. PubMed ID: 26091938
[TBL] [Abstract][Full Text] [Related]
43. Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922.
Wang CY; Guo ST; Wang JY; Yan XG; Farrelly M; Zhang YY; Liu F; Yari H; La T; Lei FX; Jin L; Zhang XD; Jiang CC
Oncotarget; 2016 Aug; 7(31):49597-49610. PubMed ID: 27391062
[TBL] [Abstract][Full Text] [Related]
44. The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer.
Bahrami A; Hesari A; Khazaei M; Hassanian SM; Ferns GA; Avan A
J Cell Physiol; 2018 Mar; 233(3):2162-2169. PubMed ID: 28407239
[TBL] [Abstract][Full Text] [Related]
45. A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.
Tan L; Tran B; Tie J; Markman B; Ananda S; Tebbutt NC; Michael M; Link E; Wong SQ; Chandrashekar S; Guinto J; Ritchie D; Koldej R; Solomon BJ; McArthur GA; Hicks RJ; Gibbs P; Dawson SJ; Desai J
Clin Cancer Res; 2023 Mar; 29(6):1017-1030. PubMed ID: 36638198
[TBL] [Abstract][Full Text] [Related]
46. Proteomic Profiling of BRAFV600E Mutant Colon Cancer Cells Reveals the Involvement of Nucleophosmin/c-Myc Axis in Modulating the Response and Resistance to BRAF Inhibition by Vemurafenib.
Grbčić P; Fučkar Čupić D; Gamberi T; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201061
[TBL] [Abstract][Full Text] [Related]
47. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G
Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688
[TBL] [Abstract][Full Text] [Related]
48. Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway.
Gross A; Niemetz-Rahn A; Nonnenmacher A; Tucholski J; Keilholz U; Fusi A
Target Oncol; 2015 Mar; 10(1):77-84. PubMed ID: 24824730
[TBL] [Abstract][Full Text] [Related]
49. Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies.
Fattore L; Marra E; Pisanu ME; Noto A; de Vitis C; Belleudi F; Aurisicchio L; Mancini R; Torrisi MR; Ascierto PA; Ciliberto G
J Transl Med; 2013 Jul; 11():180. PubMed ID: 23890105
[TBL] [Abstract][Full Text] [Related]
50. BRAF V600E is a determinant of sensitivity to proteasome inhibitors.
Zecchin D; Boscaro V; Medico E; Barault L; Martini M; Arena S; Cancelliere C; Bartolini A; Crowley EH; Bardelli A; Gallicchio M; Di Nicolantonio F
Mol Cancer Ther; 2013 Dec; 12(12):2950-61. PubMed ID: 24107445
[TBL] [Abstract][Full Text] [Related]
51. Preclinical Evaluation of Vemurafenib as Therapy for BRAF
Gouravan S; Meza-Zepeda LA; Myklebost O; Stratford EW; Munthe E
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29570692
[TBL] [Abstract][Full Text] [Related]
52. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
Joshi M; Rice SJ; Liu X; Miller B; Belani CP
PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
[TBL] [Abstract][Full Text] [Related]
53. Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.
Yaeger R; Yao Z; Hyman DM; Hechtman JF; Vakiani E; Zhao H; Su W; Wang L; Joelson A; Cercek A; Baselga J; de Stanchina E; Saltz L; Berger MF; Solit DB; Rosen N
Cancer Res; 2017 Dec; 77(23):6513-6523. PubMed ID: 28951457
[No Abstract] [Full Text] [Related]
54. BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells.
He K; Chen D; Ruan H; Li X; Tong J; Xu X; Zhang L; Yu J
Oncotarget; 2016 Jul; 7(30):47699-47710. PubMed ID: 27351224
[TBL] [Abstract][Full Text] [Related]
55. Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells.
Park JJ; Yi JY; Jin YB; Lee YJ; Lee JS; Lee YS; Ko YG; Lee M
Biochem Pharmacol; 2012 Apr; 83(7):849-57. PubMed ID: 22266356
[TBL] [Abstract][Full Text] [Related]
56. Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Wang W; Kang H; Zhao Y; Min I; Wyrwas B; Moore M; Teng L; Zarnegar R; Jiang X; Fahey TJ
J Clin Endocrinol Metab; 2017 Feb; 102(2):634-643. PubMed ID: 27754804
[TBL] [Abstract][Full Text] [Related]
57. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
58. Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib.
Cheng H; Chang Y; Zhang L; Luo J; Tu Z; Lu X; Zhang Q; Lu J; Ren X; Ding K
J Med Chem; 2014 Mar; 57(6):2692-703. PubMed ID: 24588073
[TBL] [Abstract][Full Text] [Related]
59. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O
Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972
[TBL] [Abstract][Full Text] [Related]
60. Constitutive activation of the neuregulin-1/erbB signaling pathway promotes the proliferation of a human peripheral neuroepithelioma cell line.
Fallon KB; Havlioglu N; Hamilton LH; Cheng TP; Carroll SL
J Neurooncol; 2004 Feb; 66(3):273-84. PubMed ID: 15015657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
